|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression |
ISO EXP |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC3 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA thiacloprid results in increased expression of ABCC3 mRNA |
CTD |
PMID:32745781 PMID:33426623 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP ISO |
thiacloprid results in decreased activity of ACHE protein |
CTD |
PMID:21251949 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ACOX1 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Alb |
albumin |
multiple interactions decreases expression |
EXP |
astaxanthine inhibits the reaction [thiacloprid results in decreased expression of ALB protein] |
CTD |
PMID:34564187 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression multiple interactions |
ISO EXP |
thiacloprid results in increased expression of ALDH1A1 mRNA [thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:32201337 PMID:33426623 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression |
ISO |
thiacloprid results in decreased expression of ATG5 mRNA; thiacloprid results in decreased expression of ATG5 protein |
CTD |
PMID:37468076 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Cat |
catalase |
decreases activity decreases expression multiple interactions |
EXP |
thiacloprid results in decreased activity of CAT protein thiacloprid results in decreased expression of CAT mRNA astaxanthine inhibits the reaction [thiacloprid results in decreased activity of CAT protein]; Polysaccharides inhibits the reaction [thiacloprid results in decreased activity of CAT protein]; Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of CAT mRNA] |
CTD |
PMID:28692354 PMID:34564187 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CD36 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[clothianidin co-treated with thiacloprid] results in increased expression of CES2 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein |
CTD |
PMID:32201337 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP |
thiacloprid results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; thiacloprid results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein] |
CTD |
PMID:16981889 PMID:25459289 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CPT1A mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
ISO |
thiacloprid results in decreased expression of CREM mRNA; thiacloprid results in decreased expression of CREM protein |
CTD |
PMID:37468076 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
ISO |
thiacloprid results in increased expression of CYBB mRNA |
CTD |
PMID:32201337 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
thiacloprid results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:37468076 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions affects expression |
ISO |
thiacloprid results in increased activity of CYP19A1 protein thiacloprid results in increased expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione affects the reaction [thiacloprid affects the expression of CYP19A1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [thiacloprid affects the expression of CYP19A1 mRNA] |
CTD |
PMID:26464060 PMID:28750898 PMID:29701941 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
thiacloprid results in increased expression of CYP1A1 mRNA; thiacloprid results in increased expression of CYP1A1 protein |
CTD |
PMID:21784029 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP1A2 mRNA; thiacloprid results in increased expression of CYP1A2 protein [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:21784029 PMID:32201337 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of CYP2B2 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
[clothianidin co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA thiacloprid results in increased expression of CYP2B6 mRNA [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2B10 mRNA; [Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:32201337 PMID:32736067 PMID:32745781 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases expression decreases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP2C19 mRNA thiacloprid results in decreased expression of CYP2C19 protein [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA |
CTD |
PMID:32194361 PMID:32201337 PMID:32745781 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
thiacloprid results in decreased expression of CYP2E1 mRNA [clothianidin co-treated with thiacloprid] results in increased expression of CYP2E1 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP3A4 mRNA; thiacloprid results in increased expression of CYP3A4 protein [clothianidin co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[thiacloprid co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A23-3A1 mRNA thiacloprid results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP3A5 mRNA [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein; [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO EXP |
thiacloprid results in decreased expression of CYP7A1 protein [thiacloprid co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA thiacloprid results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:32194361 PMID:33426623 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddx4 |
DEAD-box helicase 4 |
decreases expression |
ISO |
thiacloprid results in decreased expression of DDX4 mRNA; thiacloprid results in decreased expression of DDX4 protein |
CTD |
PMID:37468076 |
|
NCBI chr 2:44,227,946...44,282,867
Ensembl chr 2:44,227,946...44,282,723
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of DIO1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ECI1 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Eln |
elastin |
multiple interactions decreases expression |
EXP |
[thiacloprid co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA thiacloprid results in decreased expression of ELN mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of GFAP protein |
CTD |
PMID:32736067 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of GPT protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of GPT protein]; Polysaccharides inhibits the reaction [thiacloprid results in increased expression of GPT protein] |
CTD |
PMID:31328355 PMID:34564187 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
EXP |
Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of GPX1 mRNA] |
CTD |
PMID:28692354 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions increases expression |
EXP |
astaxanthine inhibits the reaction [thiacloprid results in increased expression of HMGB1 mRNA] |
CTD |
PMID:34564187 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of HMGCS2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of IL10 protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of IL10 protein] |
CTD |
PMID:34564187 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of IL1B protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of IL1B protein] |
CTD |
PMID:34564187 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
thiacloprid results in increased expression of IL6 protein |
CTD |
PMID:34564187 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of INS1 protein |
CTD |
PMID:32745781 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ky |
kyphoscoliosis peptidase |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of KY mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:103,086,959...103,126,305
Ensembl chr 8:103,086,630...103,126,024
|
|
G |
Megf11 |
multiple EGF-like-domains 11 |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of MEGF11 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:64,892,312...65,218,984
Ensembl chr 8:64,892,387...65,216,061
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
thiacloprid results in decreased expression of MKI67 mRNA; thiacloprid results in decreased expression of MKI67 protein |
CTD |
PMID:37468076 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mme |
membrane metallo-endopeptidase |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of MME mRNA [thiacloprid co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of NOS2 mRNA astaxanthine inhibits the reaction [thiacloprid results in increased expression of NOS2 mRNA] |
CTD |
PMID:34564187 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
NR1I3 protein affects the susceptibility to [2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with Thiophanate co-treated with thiacloprid co-treated with Ziram] |
CTD |
PMID:29950287 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of PDGFRB protein |
CTD |
PMID:32736067 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
thiacloprid results in increased expression of POR mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc16a2 |
solute carrier family 16 member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SLC16A2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases activity |
ISO |
thiacloprid metabolite results in increased activity of SLC22A1 protein; thiacloprid results in increased activity of SLC22A1 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
decreases activity |
ISO |
thiacloprid metabolite results in decreased activity of SLC22A2 protein; thiacloprid results in decreased activity of SLC22A2 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
decreases activity |
ISO |
thiacloprid metabolite results in decreased activity of SLC22A8 protein; thiacloprid results in decreased activity of SLC22A8 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of SLC6A1 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of SOD1 mRNA] |
CTD |
PMID:28692354 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
thiacloprid results in decreased expression of STAR mRNA |
CTD |
PMID:37468076 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SULT1B1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Sycp3 |
synaptonemal complex protein 3 |
decreases expression |
ISO |
thiacloprid results in decreased expression of SYCP3 mRNA; thiacloprid results in decreased expression of SYCP3 protein |
CTD |
PMID:37468076 |
|
NCBI chr 7:22,874,055...22,888,512
Ensembl chr 7:22,874,055...22,888,511
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA; [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in decreased expression of THRSP mRNA; Dietary Fats inhibits the reaction [[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA] |
CTD |
PMID:32745781 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|